Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Legal & General Group Plc

Legal & General Group Plc increased its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 367.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 146,125 shares of the company's stock after acquiring an additional 114,833 shares during the quarter. Legal & General Group Plc's holdings in Dr. Reddy's Laboratories were worth $2,307,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its position in Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd grew its position in Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after acquiring an additional 4,523,303 shares during the last quarter. Vanguard Group Inc. increased its stake in Dr. Reddy's Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Dr. Reddy's Laboratories by 462.1% in the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after purchasing an additional 2,313,987 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 402.5% in the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after buying an additional 1,977,419 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Stock Down 0.1 %

NYSE RDY traded down $0.02 during trading on Tuesday, reaching $13.93. 622,461 shares of the company's stock traded hands, compared to its average volume of 1,465,669. The firm has a market cap of $11.62 billion, a price-to-earnings ratio of 22.16 and a beta of 0.51. The company's 50 day simple moving average is $13.18 and its two-hundred day simple moving average is $14.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, sell-side analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.